An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions

Launched by BAYER · Oct 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of a medication called vericiguat in Indian people who have chronic heart failure with a condition known as reduced ejection fraction. This means that their heart is not pumping blood as well as it should, which can lead to symptoms like shortness of breath and tiredness. The researchers are looking at data from patients who have already been prescribed vericiguat as part of their regular treatment between September 2022 and August 2023. They will collect information from medical records to understand how well the medication works and if it causes any side effects, such as low blood pressure or fainting.

To be eligible for this study, patients must be at least 18 years old and have received a prescription for vericiguat during the specified time frame. The trial is not recruiting participants yet, and it will follow the patients' information until February 2024. Importantly, no extra tests or doctor visits are required for this study; researchers will only use the data that is already available from routine care. This study will help provide more real-world information about vericiguat and how it can help manage heart failure in patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients of ≥18 years age.
• • Patients who are prescribed as per local label will be included in the study
• • At least one Vericiguat prescription during the time between 01 Sep 2022 and 31 Aug 2023
• Exclusion Criteria:
• • Subjects who have participated in an interventional clinical study